Quantcast
Last updated on April 24, 2014 at 11:28 EDT

Latest Carcinoid Stories

2014-02-21 23:03:28

BerriHealth continues to support research for the neuroendocrine tumor and carcinoid cancer community. Portland, Oregon (PRWEB) February 21, 2014 BerriHealth, a leader in providing high-quality black raspberry powder for clinical trials and directly to consumers online, has donated a portion of their 2013 sales to New Orleans Louisiana Neuroendocrine Tumor Specialists (NOLANETS), led by Dr. Eugene Woltering. The program is a collaborative effort between the Louisiana State University...

2014-02-14 23:04:29

From Patient to Survivor: Author’s Medical Background and Own Cancer Experience Provides Insight and Inspiration for Rare Type of Cancer San Francisco (PRWEB) February 14, 2014 Over 90% of all carcinoid and neuroendocrine tumors are incorrectly diagnosed and treated for the wrong disease. Maria Gonzalez, MSN, FNP/PA-C, hopes to help reverse this trend by increasing the awareness of this rare and poorly understood type of cancer. Her new book, “But You Look So Good… Stories by...

2014-01-29 16:29:03

DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/q8l6jf/lexicons) has announced the addition of the "Lexicon's telotristat - A new approach to carcinoid syndrome" [http://www.researchandmarkets.com/research/q8l6jf/lexicons ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Lexicon is developing telotristat as therapy for carcinoid syndrome, an orphan' disease that occurs...

2013-06-25 23:01:51

BerriProducts LLC, an Oregon-based supplier of premium quality black raspberry products shares news from the recently-attended Berry Health Benefits Symposium on angiogenesis inhibition with an in vitro test on human carcinoid cancer cells Charlotte, North Carolina (PRWEB) June 25, 2013 Dr. Eugene Woltering, Section Chief of Surgical Endocrinology at the Louisiana State University Health Sciences Center in New Orleans presented some results of his work on neuroendocrine tumors (NETS)....

2012-10-20 04:00:03

The Philly NETs (neuroendocrine tumor cancers) and its patient community will celebrate the 3rd annual worldwide NET Cancer Awareness Day on November 10th at the Philadelphia Zoo with its inaugural 5K “Deb´s Run for The Stripes”. PhillyNETs is the sponsoring group in partnership with the Patients´ Project, a local nonprofit addressing the issue of health literacy. The Run will benefit University of Pennsylvania´s Abramson Cancer Center´s Neuroendocrine Tumor...

2012-10-12 07:23:03

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has initiated a registrational, Phase 3 clinical trial of telotristat etiprate, an investigational new drug candidate for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the...

2012-10-12 07:22:58

THE WOODLANDS, Texas, Oct. 12, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line data from a recently completed Phase 2 study in carcinoid syndrome with telotristat etiprate. Results from the trial will be presented at the North American Neuroendocrine Tumor Society on Saturday, October 13, 2012 in San Diego, California. Carcinoid syndrome is a chronic...

2012-09-19 02:31:14

SAINT GENIS POUILLY, France, September 19, 2012 /PRNewswire/ -- Highlights - Lutathera(R) is the first theragnostic drug in Molecular Nuclear Medicine (MNM) to enter phase III clinical development - First European patient enrolled on July 20,2012; first US patient expected to be enrolled in Q4 2012 - Phase II results in progressive midgut carcinoid showed Progression-Free Survival of more than 44 months...

2012-03-20 14:20:59

THE WOODLANDS, Texas, March 20, 2012 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the U.S. Food and Drug Administration (FDA) has granted its request for Orphan Drug designation for telotristat etiprate (LX1032) for the treatment of carcinoid syndrome. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract and is characterized by severe diarrhea and flushing episodes with...

2011-11-30 10:45:17

Combination treatment with octreotide shows improved results in tumors associated with carcinoid syndrome Combination treatment with everolimus, an inhibitor of the mammalian target rapamycin (mTOR), and octreotide has shown to improve progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome, according to researchers at The University of Texas MD Anderson Cancer Center. Results of the international, randomized, placebo-controlled...